硼化镁纳米颗粒通过上调BDNF减轻海马神经元及突触损伤改善糖尿病并发抑郁症小鼠行为和脑结构异常OA
Magnesium diboride nanoparticles alleviate hippocampal neurons and synapses by upregulating BDNF to improve behavioral and brain structural abnormalities in diabetes mellitus mice complicated with depression
目的 糖尿病并发抑郁症(diabetes mellitus complicated with depression,DD)是糖尿病患者常见的精神心理共病,表现为持续情绪低落以及糖代谢紊乱加重,严重影响疾病预后与患者生存质量.本研究通过构建DD小鼠模型,探讨硼化镁(MgB2)纳米颗粒对其行为和脑结构的影响.方法 本研究利用扫描电子显微镜、X射线衍射对所制备的MgB2纳米颗粒进行表征,利用氢气微电极检测该纳米颗粒在体外以及体内胃、肠组织和血液中的释氢性能,通过动物实验评估其体内安全性.40只7~8周龄雄性C57BL/6J小鼠(体质量18~23 g)按照随机数字表法分为对照(Control)组、模型(DD)组、20 mg/kg MgB2组、30 mg/kg MgB2组和40 mg/kg MgB2组.DD组和3个不同剂量的MgB2组小鼠通过一次性腹腔注射链脲佐菌素(streptozotocin,STZ,150 mg/kg),在第5 d测空腹血糖(fasting blood glucose,FBG),若FBG≥11.3 mmol/L则持续喂养7 d,随后连续7 d腹腔注射脂多糖(lipopolysaccharide,LPS,0.5 mg/kg)来构建DD小鼠模型,Control组小鼠注射等剂量的柠檬酸-柠檬酸钠缓冲溶液.DD造模成功后,MgB2组小鼠连续灌胃对应剂量的MgB2纳米颗粒治疗7 d,其余组小鼠灌胃等体积的生理盐水.末次灌胃治疗24 h后通过行为学实验确定最佳治疗剂量.最佳MgB2纳米颗粒剂量治疗后检测小鼠体质量、血清葡萄糖(glucose,GLU)含量;脑部MRI观察小鼠海马体体积、各向异性分数(fractional anisotropy,FA)和平均弥散系数(mean diffusivity,MD);ELISA检测小鼠海马脑源性神经营养因子(brain-derived neurotrophic factor,BDNF);透射电子显微镜观察海马超微结构的变化.结果 MgB2纳米颗粒在酸性条件下具有优异释氢特性,且释放过程均匀稳定.该材料兼具高储氢效能和安全性,可在胃内快速释放,在肠组织中缓慢释放,在血液中维持稳定.在旷场实验中,3个不同剂量的MgB2组小鼠在中央区域和外周区域的运动距离和穿格次数较DD组显著增加(P<0.01);在高架十字迷宫实验中,3个不同剂量的MgB2组小鼠在开放臂上的停留时间与运动距离较DD组显著增加(P<0.05),在封闭臂上的停留时间显著降低、运动距离较DD组显著增加(P<0.01);在悬尾实验和强迫游泳实验中,3个不同剂量的MgB2组小鼠的不动时间较DD组显著缩短(P<0.01).以上行为学实验结果发现3种剂量的MgB2纳米颗粒组间疗效相当,因此选择20 mg/kg作为MgB2纳米颗粒的最佳治疗剂量.与DD组相比,MgB2纳米颗粒能够有效增加小鼠的体质量[(21.85±1.24)vs(19.30±1.20)g,P<0.01]、海马体积[(3.77±0.68)vs(2.63±0.47)mm3,P<0.01]、BDNF[(2 295.78±259.47)vs(1 913.69±262.05)pg/mL,P<0.05]和 FA(左 侧:0.23±0.03 vs 0.16±0.02;右侧:0.22±0.04 vs 0.15±0.02,P<0.01),降低血清GLU含量[(25.97±4.66)vs(38.25±8.42)mmol/L,P<0.01]和MD[左侧:(5.11±0.09)×10-4 vs(5.42±0.23)×10-4 mm2/s;右侧:(5.19±0.45)×10-4 vs(5.60±0.27)×10-4 mm2/s,P<0.05],使得海马神经元核膜完整、核内染色质较均匀,细胞器较丰富,海马突触数量增加(5.33±1.22 vs 3.56±1.50,P<0.05),突触间隙增加[(21.66±2.72)vs(17.23±2.69)nm,P<0.01],结构较为清晰.结论 MgB2纳米颗粒通过上调BDNF水平,减少对海马神经元和突触的损伤,从而改善DD小鼠的行为和脑结构异常.
Objective Diabetes mellitus complicated with depression(DD)is a common psychiatric comorbidity in diabetic patients,characterized by persistent low mood and disordered glucose metabolism,which severely impacts disease prognosis and patient's quality of life.This study aims to investigate the effects of magnesium diboride(MgB2)nanoparticles on the behavior and brain structure of mice in a mouse model of DD.Methods Scanning electron microscopy and X-ray diffraction were performed to characterize the prepared MgB2 nanoparticles,and hydrogen microelectrodes were employed to detect the hydrogen release properties of the nanoparticles in vitro and in the gastric,intestinal,and blood tissues in mice.In vivo safety was evaluated through animal experiments.Forty male C57BL/6J mice(7 to 8 weeks old,weighing 18 to 23 g)were randomly divided into a Control group,a model(DD)group,and 20,30 and 40 mg/kg MgB2 groups.The mice in the DD group and the 3 MgB2 groups were administered a single intraperitoneal injection of streptozotocin(STZ,150 mg/kg),and fasting blood glucose(FBG)was measured on day 5.If FBG was≥11.3 mmol/L,the mice were fed continuously for 7 d,followed by consecutive intraperitoneal injections of lipopolysaccharide(LPS,0.5 mg/kg)for 7 d to establish the DD mouse model,while the mice in the Control group were injected with an equal dose of citric acid-sodium citrate buffer.After successful DD modeling,the mice in the MgB2 groups were intragastrically administered corresponding doses of MgB2 nanoparticles for 7 consecutive days,while the mice in the other groups were given an equivalent volume of normal saline by gavage.Behavioral tests were performed 24 h after the final administration to determine the optimal therapeutic dose.Following treatment with the optimal dose of MgB2 nanoparticles,body weight and serum glucose(GLU)levels were measured.Brain MRI scanning was performed to assess hippocampal volume,fractional anisotropy(FA)and mean diffusivity(MD).Hippocampal brain-derived neurotrophic factor(BDNF)levels were measured by ELISA.Changes in hippocampal ultrastructure were observed by transmission electron microscopy.Results MgB2 nanoparticles exhibited excellent hydrogen release properties under acidic conditions,with a uniform and stable release process.The nanoparticles possessed both high hydrogen storage capacity and safety,enabling rapid hydrogen release in the stomach,slow release in intestinal tissue,and stable maintenance in the blood.In the open field test,the mice in the 3 MgB2 groups showed significant increases in the traveled distance and the crossing numbers in both the central and peripheral zones compared with the DD group(P<0.01).In the elevated plus maze test,treatment of MgB2 nanoparticles resulted in increased time spent and traveled distance on the open arms compared with those in the DD group(P<0.05),decreased time spent and more traveled distance in the closed arms compared with that in the DD group(P<0.01).In the tail suspension and forced swim tests,the immobility time of mice in the 3 different MgB2 dose groups was significantly shorter than that of the DD group(P<0.01).These behavioral findings indicated comparable efficacy among the 3 MgB2 nanoparticle doses;consequently,20 mg/kg was selected as the optimal therapeutic dose.Compared with the DD group,MgB2 nanoparticles effectively increased body weight[(21.85±1.24)vs(19.3±1.20)g,P<0.01]hippocampal volume[(3.77±0.68)vs(2.63±0.47)mm3,P<0.01],BDNF expression[(2 295.78±259.47)vs(1 913.69±262.05)pg/mL,P<0.05],and FA(Left side:0.23±0.03 vs 0.16±0.02;right side:0.22±0.04 vs 0.15±0.02,P<0.01),while reducing serum GLU levels[(25.97±4.66)vs(38.25±8.42)mmol/L,P<0.01],and MD[Left side:(5.11±0.09)×10-4 vs(5.42±0.23)×10-4 mm2/s;right side:(5.19±0.45)×10-4 vs(5.60±0.27)×10-4 mm2/s,P<0.05].These improvements resulted in intact nuclear membranes in hippocampal neurons,relatively uniform intranuclear chromatin,abundant organelles,increased number of hippocampal synapses(5.33±1.22 vs 3.56±1.50,P<0.05),elevated synaptic cleft width[(21.66±2.72)vs(17.23±2.69)nm,P<0.01],and clearer structural features.Conclusion MgB2 nanoparticles improve behavioral and structural abnormalities in the brains of DD mice by upregulating BDNF levels and reducing damage to hippocampal neurons and synapses.
左晓飞;范华菊;吴倩盈;殷昊;陈琪椿;张华鑫;潘文青;王英帅;杨娜娜
山东第二医科大学:生命科学与技术学院,山东潍坊四川省第二退伍军人医院心理健康服务中心,四川成都山东第二医科大学:生命科学与技术学院,山东潍坊山东第二医科大学:生命科学与技术学院,山东潍坊山东第二医科大学:生命科学与技术学院,山东潍坊山东第二医科大学:生命科学与技术学院,山东潍坊山东第二医科大学:基础医学院,山东潍坊山东第二医科大学:生命科学与技术学院,山东潍坊山东第二医科大学:生命科学与技术学院,山东潍坊
医药卫生
MgB2糖尿病并发抑郁症海马脑源性神经营养因子
MgB2diabetes mellitus complicated with depressionhippocampusbrain-derived neurotrophic factor
《陆军军医大学学报》 2026 (17)
2440-2452,13
国家自然科学基金青年科学基金项目(81600360)山东省自然科学基金重点项目(ZR2020KH008)山东省自然科学基金创新发展联合基金项目(ZR2024LSW011)鸢都学者课题(000007060)江苏悟空生物科技有限公司横向项目(02191004) Supported by the National Natural Science Foundation for Young Scholars of China(81600360),the Key Project of Natural Science Foundation of Shandong Province(ZR2020KH008),the Joint Innovation and Development Project of Natural Science Foundation of Shandong Province(ZR2024LSW011),the Yuandu Scholar Foundation(000007060),and the Horizontal Project Funded by Jiangsu Wukong Biotechnology Co.,LTD(02191004).
评论